Mifepristone
- Generic Name
- Mifepristone
- Brand Names
- Korlym, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35NO2
- CAS Number
- 84371-65-3
- Unique Ingredient Identifier
- 320T6RNW1F
- Background
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...
- Indication
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
- Associated Conditions
- Hyperglycemia
- Associated Therapies
- Medically induced abortion
Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Check, Jerome H., M.D., Ph.D.
- Target Recruit Count
- 3
- Registration Number
- NCT02642939
- Locations
- 🇺🇸
Cooper Institute for Reproductive Hormonal Disorders, Melrose Park, Pennsylvania, United States
Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 200
- Registration Number
- NCT02633761
- Locations
- 🇲🇽
Hospital General "Enrique Cabrera", Mexico City, Mexico
🇲🇽National Institute of Perinatology (INPer), Mexico City, Mexico
🇻🇳National Ob-Gyn Hospital, Hanoi, Vietnam
Mifepristone Induction for Fetal Demise
- Conditions
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02620904
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT02412618
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Roger Goldberg, M.D., MBA
- Target Recruit Count
- 16
- Registration Number
- NCT02354170
- Locations
- 🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 416
- Registration Number
- NCT02342002
- Locations
- 🇦🇷
Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina
🇬🇦CHU Libreville, Libreville, Gabon
🇲🇽Hospital General Valle Ceylan, Tlalnepantla, Mexico
Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Mediterranea Medica S. L.
- Target Recruit Count
- 360
- Registration Number
- NCT02271958
- Locations
- 🇨🇺
Hospital Eusebio Hernández, "Maternidad Obrera", Havana, Cuba
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 31
- Registration Number
- NCT02046421
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 88
- Registration Number
- NCT02012296
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Cancer Care Specialists of Central Illinois (Decatur) /Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
Comparative Effectiveness of Pregnancy Failure Management Regimens
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 300
- Registration Number
- NCT02012491
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.